Overexpression of Protein Kinase C-delta and -epsilon in NIH 3T3 Cells Induces Opposite Effects on Growth, Morphology, Anchorage Dependence, and Tumorigenicity
Overview
Authors
Affiliations
We have determined the patterns of mRNA and protein expression of 7 protein kinase C (PKC) isozymes in NIH 3T3 cells. Only PKC-alpha is expressed abundantly in NIH 3T3 cells; endogenous levels of the other 6 PKC isozymes are low or undetectable. We have overexpressed PKC-delta and -epsilon in these cells to observe activation/translocation of these two isozymes and the biological consequences of overexpression. Both PKC-delta and -epsilon, but not PKC-alpha, are partially associated with the insoluble fraction even in the absence of phorbol 12-myristate 13-acetate (PMA). Upon PMA stimulation, both PKC-delta and -epsilon translocate to the insoluble fraction of cell homogenates, as can be observed with the endogenous PKC-alpha. Overexpression of PKC-delta induces significant changes in morphology and causes the cells to grow more slowly and to a decreased cell density in confluent cultures. These changes are accentuated by treatment with PMA. Overexpression of PKC-epsilon does not lead to morphological changes, but causes increased growth rates and higher cell densities in monolayers. None of the PKC-delta overexpressers grow in soft agar with or without PMA, but all the cell lines that overexpress PKC-epsilon grow in soft agar in the absence of PMA, but not in its presence. NIH 3T3 cells that overexpress PKC-epsilon also form tumors in nude mice with 100% incidence. This indicates that high expression of PKC-epsilon contributes to neoplastic transformation.
Liu Y, Lin L, Zheng H, He Y, Li Y, Zhou C Mar Drugs. 2023; 21(3).
PMID: 36976205 PMC: 10056024. DOI: 10.3390/md21030156.
Judge P, Overall S, Barnes A Int J Mol Sci. 2023; 24(5).
PMID: 36902029 PMC: 10002858. DOI: 10.3390/ijms24054598.
Nicholson R, Menezes A, Azevedo A, Leckenby A, Davies S, Seedhouse C Front Oncol. 2022; 12:840046.
PMID: 35707351 PMC: 9191576. DOI: 10.3389/fonc.2022.840046.
Role and Mechanism of PKC-δ for Cardiovascular Disease: Current Status and Perspective.
Miao L, Pan D, Shi J, Du J, Chen P, Gao J Front Cardiovasc Med. 2022; 9:816369.
PMID: 35242825 PMC: 8885814. DOI: 10.3389/fcvm.2022.816369.
A cancer-associated, genome protective programme engaging PKCε.
Parker P, Lockwood N, Davis K, Kelly J, Soliman T, Pardo A Adv Biol Regul. 2020; 78:100759.
PMID: 33039823 PMC: 7689578. DOI: 10.1016/j.jbior.2020.100759.